Chan Chun, Du Shi, Dong Yizhou, Cheng Xiaolin
Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States.
Division of Pharmaceutics and Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States.
Curr Top Med Chem. 2021;21(2):92-114. doi: 10.2174/1568026620666201126162945.
Lipid nanoparticles (LNPs) have been widely applied in drug and gene delivery. More than twenty years ago, Doxil was the first LNPs-based drug approved by the US Food and Drug Administration (FDA). Since then, with decades of research and development, more and more LNP-based therapeutics have been used to treat diverse diseases, which often offer the benefits of reduced toxicity and/or enhanced efficacy compared to the active ingredients alone. Here, we provide a review of recent advances in the development of efficient and robust LNPs for drug/gene delivery. We emphasize the importance of rationally combining experimental and computational approaches, especially those providing multiscale structural and functional information of LNPs, to the design of novel and powerful LNP-based delivery systems.
脂质纳米颗粒（LNPs）已广泛应用于药物和基因递送。二十多年前，多西紫杉醇脂质体（Doxil）是首个获得美国食品药品监督管理局（FDA）批准的基于LNPs的药物。从那时起，经过数十年的研发，越来越多基于LNP的疗法被用于治疗各种疾病，与单独使用活性成分相比，这些疗法通常具有降低毒性和/或提高疗效的优势。在此，我们综述了用于药物/基因递送的高效且稳定的LNPs开发的最新进展。我们强调合理结合实验和计算方法的重要性，特别是那些能够提供LNPs多尺度结构和功能信息的方法，对于设计新型且强大的基于LNP的递送系统的重要性。
